Liminatus Pharma, Inc. Class A Common Stock (LIMN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.02M
Last updated: Nov 17, 2026 at 11:04 AM ET
Liminatus Pharma, Inc. Class A Common Stock (LIMN) Financials: Revenue, Profit and Cash Flow
Liminatus Pharma, Inc. Class A Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$10.21M, operating cash flow was -$9.96M and free cash flow was -$9.98M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of -$1.41M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $2.97M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0 | N/A | N/A | N/A | N/A |
| Dec 2024 | $0 | N/A | N/A | N/A | N/A |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Research and development | $0 | $2.69M | $3.76M | $1.85M | $3.80M |
| Operating income | -$2.97M | -$3.33M | -$2.59M | -$2.71M | -$2.53M |
| Net income | -$10.21M | -$3.55M | -$1.23M | -$2.93M | $4.37M |
| EBITDA | N/A | -$3.33M | -$1.09M | -$2.71M | $4.37M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit | $0 | $0 | $255 | $0 | $0 | $0 | N/A | $0 | $0 | $0 | N/A | N/A |
| Operating income | -$1.38M | -$1.10M | -$1.15M | -$701.17K | -$1.12M | -$264.22K | -$1.88M | -$543.15K | -$909.22K | -$247 | -$642.70K | -$676.32K |
| Net income | -$1.41M | -$1.12M | -$8.50M | -$1.82M | $113.29K | -$327.53K | -$1.98M | -$601.37K | -$961.21K | -$247 | -$486.60K | -$323.89K |
Balance Sheet
As of Dec 2025, short-term debt of $1.44M exceeded cash and equivalents by $1.10M. Shareholder equity was negative, at -$9.81M, as total liabilities of $10.33M exceeded total assets of $512.79K.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total assets | $512.79K | $5.41M | $4.50M | $15.49M | $276.44M |
| Current assets | $500.57K | $5.28M | $210.88K | $360.65K | $421.92K |
| Cash and equivalents | $337.65K | $56.32K | $434.00K | $5.05M | $336.23K |
| Total liabilities | $10.33M | $24.75M | $15.19M | $14.19M | $21.57M |
| Short-term debt | $1.44M | $19.97M | $16.05M | $16.50M | $90.00K |
| Shareholder equity | -$9.81M | -$19.34M | -$10.69M | $1.29M | $254.87M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.40M | $2.79M | $512.79K | $1.34M | $1.91M | $0 | $5.41M | $3.07M | $3.54M | $4.63M | $4.50M | $4.56M |
| Total liabilities | $3.10M | $2.92M | $10.33M | $2.99M | $10.72M | $1.06K | $24.75M | $17.32M | $16.61M | $17.16M | $15.19M | $14.76M |
| Cash and equivalents | $3.02M | $1.91M | $337.65K | $724.50K | $1.34M | $804.54K | $56.32K | $358.18K | $339.20K | $1.47M | $434.00K | $337.72K |
| Shareholder equity | $300.61K | -$132.60K | -$9.81M | -$1.65M | -$8.81M | -$1.06K | -$19.34M | -$14.25M | -$13.07M | -$12.53M | -$10.69M | -$10.21M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$9.96M | -$1.45M | -$3.35M | -$869.00K | -$1.22M |
| Capital expenditures | $13.11K | $0 | $0 | $0 | $0 |
| Free cash flow | -$9.98M | -$1.45M | -$3.35M | -$869.00K | -$1.22M |
| Dividends paid | $2.56M | $0 | N/A | N/A | N/A |
| Investing cash flow | -$788.11K | -$2.85M | -$819.00K | $263.96M | -$276.00M |
| Financing cash flow | $11.03M | $3.92M | -$450.00K | $5.92M | $277.55M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$970.00K | -$2.02M | -$386.85K | -$600.61K | -$8.82M | -$159.39K | -$140.66K | -$206.12K | -$1.10M | $0 | -$627.10K | -$539.35K |
| Capital expenditures | N/A | $0 | $0 | $13.11K | $0 | $0 | $5 | $5 | $3 | $0 | $1 | $3 |
| Free cash flow | N/A | -$2.02M | -$386.85K | -$613.72K | -$8.82M | -$159.39K | -$140.66K | -$206.12K | -$1.10M | $0 | -$627.10K | -$539.36K |
Frequently Asked Questions About LIMN
What is Liminatus Pharma, Inc. Class A Common Stock's annual revenue?
Liminatus Pharma, Inc. Class A Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025.
Is Liminatus Pharma, Inc. Class A Common Stock profitable?
No. Liminatus Pharma, Inc. Class A Common Stock reported net income of -$10.21M for the fiscal year ended Dec 31, 2025.
How much free cash flow does LIMN generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$9.96M minus capital expenditures of $13.11K produced free cash flow of -$9.98M.
How much debt does Liminatus Pharma, Inc. Class A Common Stock have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $1.44M and cash and equivalents of $337.65K.
LIMN pages: Overview, Financials, Competitors